
Vidofludimus calcium has shown anti-inflammatory effects in clinical trials of autoimmune diseases and recently demonstrated antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The primary endpoint was the need for invasive ventilation after 28 days. These findings support vidofludimus calcium being safe and well tolerated in patients with COVID-19.
Like
Save
Share